Sign in
Not yet recruitingPhase 2

Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients

Key facts

Who runs it
University of British Columbia
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
1 May 2025
Expected to end
30 Apr 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Lemborexant 5 mg
  • Control (placebo) group
Record updated
23 April 2025

Who can take part

Age
61 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Admitted to hospital following open cardiac surgery through midline sternotomy

Who cannot take part

  • ● Known severe obstructive sleep apnea diagnosed by polysomnography or STOPBANG score > 5; Periodic limb movement disorder or restless legs syndrome; Narcolepsy; Somnolence (Pasero Opioid Sedation Scale (POSS) >2); Current alcohol or substance use disorder as defined by the DSM-V; Patient already taking moderate or strong CYP3A inhibitors; Frequent use of medications for insomnia defined as >4 days per week; Liver failure (Child-Pugh score B or C); Renal failure (eGFR<30 ml/min/1.73 m2); Pre-existing delirium (ICDSC score >3 or CAM/CAM-ICU positive) at time of consent; BMI>40 kg/m2; Known allergy or hypersensitivity to study drug; Inability to communicate in English

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Post-operative delirium is a common complication following cardiac surgery and is associated with increased 1 year mortality. Currently there are no drug therapies to prevent delirium. Orexin is a neuromodulator thought to play an important role in disordered sleep, one of the instigators of delirium. Lembrorexant is an orexin antagonist, originally approved for sleep, that may also reduce the incidence of delirium. The Investigators propose a pilot study to determine the feasibility of a randomized controlled trial comparing Lembrorexant to placebo in patients following cardiac surgery in reducing the incidence of delirium, and improving sleep.

The 2 groups in the trial

  • InterventionTreatment being tested

    The intervention arm will receive the study drug, Lemborexant 5mg, daily for 7 days post-operatively while in hospital.

    Treatment: Lemborexant 5 mg

  • ControlPlacebo, for comparison

    The Control arm will receive the placebo study drug daily for 7 days post-operatively while in hospital.

    Treatment: Control (placebo) group

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized Trial of Lemborexant for the Prevention of Delirium After Cardiac Surgery (PROTEX): A Pilot Study
Record updated
23 April 2025